5-溴-N-甲基-2-呋喃酰胺 | 31136-78-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 5-溴-N-甲基-2-呋喃酰胺
• 英文名称: N-methylfuran-2-bromo-5-carboxamide
• 英文别名: 5-bromo-furan-2-carboxylic acid methylamide；5-bromo-N-methylfuran-2-carboxamide
• CAS: 31136-78-4
• 化学式: C₆H₆BrNO₂
• mdl: MFCD06093352
• 分子量: 204.023
• InChiKey: QMUCVHLODHSPLZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2932190090

反应信息

• 作为反应物：
  描述：

  5-溴-N-甲基-2-呋喃酰胺 在 chloro(1,5-cyclooctadiene)rhodium(I) dimer 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 N-甲基二环己基胺 、 四丁基氯化铵 、 三乙胺 作用下， 以 1,4-二氧六环 、 N,N-二甲基乙酰胺 、 水 为溶剂， 反应 31.0h， 生成 methyl 3-(3-{[(R)-4-ethyl-1,1-dioxido-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl]methyl}-4-methylphenyl)-3-[5-(methylcarbamoyl) furan-2-yl]propanoate
  参考文献：
  名称：

  NRF2-ACTIVATING COMPOUND

  摘要：

  A compound having Nrf2-activating action is provided. The compound is represented by formula (I), a salt of the compound, or a solvate of the compound or salt: wherein R 1a and R 1b are identical or different and represent a hydrogen atom, an alkyl group, or a halogen atom; R 2 represents an optionally substituted group derived from a heterocycle, and the heterocycle represents thiophene, furan, pyrrole, thiazole, or a fused ring including any of these heterocycles; R 4 and R 5 are identical or different and represent a hydrogen atom or an optionally substituted alkyl group, or R 4 and R 5 bind with each other to form —NH—CH—N—; R 6 represents an optionally substituted alkyl group; A 1 , A 2 , A 3 , and A 4 are identical or different and represent CH or N wherein the number of N is 1 or less; and Z represents a hydrogen atom or a halogen atom.

  公开号：

  US20230024995A1
• 作为产物：
  描述：

  5-溴-2-糠酸 在 盐酸甲胺 、 1-羟基苯并三唑 、 三乙胺 作用下， 生成 5-溴-N-甲基-2-呋喃酰胺
  参考文献：
  名称：

  NRF2-ACTIVATING COMPOUND

  摘要：

  Compounds represented by formula (I), compounds of the less-polar group of two groups of diastereomers in which the carbon atom indicated by * in formula (II) is an asymmetric carbon atom, salts of the compounds, and solvates of the compounds or salts. The compounds have Nrf2 activating action.

  公开号：

  US20240132519A1

文献信息

• Antiproliferative compounds and therapeutic uses thereof
  申请人：Università Degli Studi Di Milano - Bicocca

  公开号：EP2107054A1

  公开（公告）日：2009-10-07

  Inhibitors of the oncogenic tyrosine kinase ALK and of the Bcr-Abl mutant T315I Bcr-Abl, such as a compound of formula (I): wherein Q, T, W, K, J, Y, X, Z are independently selected from C, N, S, O, provided that the corresponding rings are (hetero)aromatic; n = 0 or 1; q = 1 or 2; pharmaceutical compositions containing the same and their use for the treatment of hyper-proliferative diseases.

  抑制癌基因酪氨酸激酶ALK和Bcr-Abl突变体T315I Bcr-Abl的抑制剂，例如式(I)的化合物： 其中Q、T、W、K、J、Y、X、Z分别独立选择自C、N、S、O，前提是相应的环是(杂)芳香的； n = 0或1； q = 1或2； 含有相同化合物的药物组合物及其用于治疗高增殖性疾病。
• EP2 RECEPTOR AGONISTS
  申请人：Oxford Alexander William

  公开号：US20100130556A1

  公开（公告）日：2010-05-27

  A compound of formula (III): or a salt, solvate and chemically protected form thereof, wherein: R 5 is an optionally substituted C 5-20 aryl or C 4-20 alkyl group; L′ is a single bond, —O— or —C(═O)—; A is selected from the group consisting of: formulae (i) (ii) (iii) wherein X and Y are selected from the group consisting of: O and CR 3 ; S and CR 3 ; NH and CR 3 ; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; D is selected from: formulae (i) (ii) (iii) (iv) (v) (vii) (viii) (ix) B is selected from the group consisting of: formulae (A) (B) where R P6 is selected from fluoro and chloro; and R 2 is either: (i) —CO 2 H; (ii) —CONH 2 ; (iii) —CH 2 —OH; or (iv) tetrazol-5-yl.

  公式（III）的化合物：或其盐、溶剂合物和化学保护形式，其中：R5是可选择取代的C5-20芳基或C4-20烷基基团；L′是单键，—O—或—C(═O)—；A选自以下组：式（i）（ii）（iii），其中X和Y选自以下组：O和CR3；S和CR3；NH和CR3；NH和N；O和N；S和N；N和S；和N和O，其中虚线表示适当位置的双键，Q是N或CH；D从以下中选择：式（i）（ii）（iii）（iv）（v）（vii）（viii）（ix）B从以下组中选择：式（A）（B），其中RP6选自氟和氯；R2是：（i）—CO2H；（ii）—CONH2；（iii）—CH2—OH；或（iv）四唑-5-基。
• ANTIPROLIFERATIVE COMPOUNDS AND THERAPEUTIC USES THEREOF
  申请人：Gambacorti Passerini Carlo

  公开号：US20110112110A1

  公开（公告）日：2011-05-12

  Inhibitors of the oncogenic tyrosine kinase ALK and of the Bcr-Abl mutant T315I Bcr-Abl, pharmaceutical compositions containing the same and their use for the treatment of hyper-proliferative diseases.

  抑制癌基因酪氨酸激酶ALK和Bcr-Abl突变体T315I Bcr-Abl的抑制剂，包含它们的制药组合物以及它们用于治疗高增殖性疾病的用途。
• EP2 Receptor Agonists
  申请人：Oxford Alexander William

  公开号：US20100261760A1

  公开（公告）日：2010-10-14

  The disclosure provides EP2 receptor agonist compounds and methods for using the compounds for treating conditions which can be alleviated by agonism of an EP2 receptor.

  本公开提供EP2受体激动剂化合物以及使用这些化合物来治疗可以通过EP2受体激动治疗缓解的疾病的方法。
• Rhodium-Catalyzed Oxidative Cycloaddition of Benzamides and Alkynes via C−H/N−H Activation
  作者：Todd K. Hyster、Tomislav Rovis

  DOI：10.1021/ja103776u

  日期：2010.8.4

  The oxidative cycloaddition of benzamides and alkynes has been developed. The reaction utilizes Rh(III) catalysts in the presence of Cu(II) oxidants, and is proposed to proceed by N-H metalation of the amide followed by ortho C-H activation. The resultant rhodacycle undergoes alkyne insertion to form isoquinolones in good yield. The reaction is tolerant of extensive substitution on the amide, alkyne, and arene, including halides, silyl ethers, and unprotected aldehydes as substituents. Unsymmetrical alkynes proceed with excellent regioselectivity, and heteroaryl carboxamides are tolerated leading to intriguing scaffolds for medicinal chemistry. A series of competition experiments shed further light on the mechanism of the transformation and reasons for selectivity.